{
  "relevance_rule": {},
  "priority_rules": [
    {
      "priority": "High",
      "rule_text": "All ADCs in prostate cancer, but especially B7H3, HER-2, HER-3, and TROP2; Radioligands (RLT), CD28, KLK2, CD3, STEAP1, STEAP2, Novel PARPs, PSMA, EZH2, PRC2, AR PROTAC",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "ADC",
          "B7H3",
          "HER-2",
          "HER-3",
          "TROP2",
          "Radioligands",
          "RLT",
          "CD28",
          "KLK2",
          "CD3",
          "STEAP1",
          "STEAP2",
          "Novel PARP",
          "PSMA",
          "EZH2",
          "PRC2",
          "AR PROTAC"
        ],
        "categories": [
          "modality",
          "MOA"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "prostate",
        "mCRPC",
        "mCSPC"
      ],
      "reasoning": "Direct keyword matching for modalities and MOAs; all keywords are present in client list. Excludes low priority terms."
    },
    {
      "priority": "High",
      "rule_text": "RLTS: Ga-68-NGUL / Lu-177-DGUL; FPI-2265, CONV01-\u03b1; 225Ac-J591; [255Ac]Ac-PSMA-R2; 225Ac-PSMA-617; [225Ac]Ac-FL-020; Ludotadipep (177Lu-FC705); BAY2315497, 225Ac-pelgifatamab (BAY3546828); 225Ac-PSMA-Trillium (BAY3563254); 177Lu-rhPSMA-10.1; 64Cu-SAR-BBN and 67CU SAR-BBN, 177Lu-TLX591; 225Ac-TLX592; Pluvicto (Lu-PSMA-617); [225Ac]-AZD2284; 64Cu-SAR-bisPSMA; 67Cu-SAR-bisPSMA; 177Lu-PSMA-I&T; 68Ga-OncoACP3\n\nIO: JANX007; Xaluritamig (AMG509); REGN5678; REGN4336; REGN7075; ONC-392; Vudalimab; SX-682; Lorigerlimab; BMS-986460; AZD0754; SV-102; CAN-2409; VIR-5500; INKmune; GSK5458514; PT-112\n\nADCs: FOR46; BNT324/DB-1311; ABBV-969; infinatamab deruxtecan (I-Dxd), vobramitamab duocarmizine; ADRX-0405\n\nOther: Xtandi (enzalutamide), Nubeqa (darolutamide), saruparib (AZD-5305), Talzenna (talazoparib), Rubraca (rucaparib), cabozantinib, mevrometostat, BMS-986365; opevesostat; ORIC-944; (R)-9bMS; ART-101; ACE-232; ARC-706; ASP5541; GDC-2992 / RO7656594",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "Ga-68-NGUL",
          "Lu-177-DGUL",
          "FPI-2265",
          "CONV01-\u03b1",
          "225Ac-J591",
          "[255Ac]Ac-PSMA-R2",
          "225Ac-PSMA-617",
          "[225Ac]Ac-FL-020",
          "Ludotadipep (177Lu-FC705)",
          "BAY2315497",
          "225Ac-pelgifatamab (BAY3546828)",
          "225Ac-PSMA-Trillium (BAY3563254)",
          "177Lu-rhPSMA-10.1",
          "64Cu-SAR-BBN",
          "67CU SAR-BBN",
          "177Lu-TLX591",
          "225Ac-TLX592",
          "Pluvicto (Lu-PSMA-617)",
          "[225Ac]-AZD2284",
          "64Cu-SAR-bisPSMA",
          "67Cu-SAR-bisPSMA",
          "177Lu-PSMA-I&T",
          "68Ga-OncoACP3",
          "JANX007",
          "Xaluritamig (AMG509)",
          "REGN5678",
          "REGN4336",
          "REGN7075",
          "ONC-392",
          "Vudalimab",
          "SX-682",
          "Lorigerlimab",
          "BMS-986460",
          "AZD0754",
          "SV-102",
          "CAN-2409",
          "VIR-5500",
          "INKmune",
          "GSK5458514",
          "PT-112",
          "FOR46",
          "BNT324/DB-1311",
          "ABBV-969",
          "infinatamab deruxtecan (I-Dxd)",
          "vobramitamab duocarmizine",
          "ADRX-0405",
          "Xtandi (enzalutamide)",
          "Nubeqa (darolutamide)",
          "saruparib (AZD-5305)",
          "Talzenna (talazoparib)",
          "Rubraca (rucaparib)",
          "cabozantinib",
          "mevrometostat",
          "BMS-986365",
          "opevesostat",
          "ORIC-944",
          "(R)-9bMS",
          "ART-101",
          "ACE-232",
          "ARC-706",
          "ASP5541",
          "GDC-2992 / RO7656594"
        ],
        "categories": [
          "competitor assets"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "prostate",
        "mCRPC",
        "mCSPC"
      ],
      "reasoning": "Direct keyword matching for competitor assets; all keywords are present in client list. Excludes low priority terms."
    },
    {
      "priority": "High",
      "rule_text": "ENZARAD, PrTK03, DASL-HiCaP, EMBARK, ARASTEP, PSMA-DC, ARANOTE, Capitello-281, TALAPRO-3, PSMAddition, EvoPAR-PRO1, PROpel, TALAPRO-2, TRITON-3, CONTACT-02, PSMAfore, ECLIPSE, SPLASH, CAPitello-280, ProstACT, MEVPRO-1, MEVPRO-2, MEVPRO-3; ALPHABREAK, ARASEC; AcTFirst; PSMAcTION; PSMAndARPI; CONVERGE-01; SatisfACtion; Ideate-Prostate01; rechArge; OMAHA1; OMAHA2; XALute",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "ENZARAD",
          "PrTK03",
          "DASL-HiCaP",
          "EMBARK",
          "ARASTEP",
          "PSMA-DC",
          "ARANOTE",
          "Capitello-281",
          "TALAPRO-3",
          "PSMAddition",
          "EvoPAR-PRO1",
          "PROpel",
          "TALAPRO-2",
          "TRITON-3",
          "CONTACT-02",
          "PSMAfore",
          "ECLIPSE",
          "SPLASH",
          "CAPitello-280",
          "ProstACT",
          "MEVPRO-1",
          "MEVPRO-2",
          "MEVPRO-3",
          "ALPHABREAK",
          "ARASEC",
          "AcTFirst",
          "PSMAcTION",
          "PSMAndARPI",
          "CONVERGE-01",
          "SatisfACtion",
          "Ideate-Prostate01",
          "rechArge",
          "OMAHA1",
          "OMAHA2",
          "XALute"
        ],
        "categories": [
          "trial names"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "prostate",
        "mCRPC",
        "mCSPC"
      ],
      "reasoning": "Direct keyword matching for trial names; all keywords are present in client list. Excludes low priority terms."
    },
    {
      "priority": "High",
      "rule_text": "ARPI (androgen receptor pathway inhibitors), androgen deprivation therapy, androgen receptor degraders, all PARP mentions",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "ARPI (androgen receptor pathway inhibitors)",
          "androgen deprivation therapy",
          "androgen receptor degraders",
          "PARP",
          "PARP inhibitor"
        ],
        "categories": [
          "new additions"
        ],
        "contextual_concepts": []
      },
      "exclusions": [
        "prostate",
        "mCRPC",
        "mCSPC"
      ],
      "reasoning": "Direct keyword matching for new additions; all keywords are present in client list. Excludes low priority terms."
    },
    {
      "priority": "High",
      "rule_text": "Within a session, if any of the breakout titles are assigned a High priority, assign the same priority to its Q&A or discussion session",
      "approach": "context",
      "key_concepts": {
        "keywords": [],
        "categories": [],
        "contextual_concepts": [
          "session structure",
          "breakout title",
          "Q&A",
          "discussion session",
          "inheritance of priority"
        ]
      },
      "exclusions": [],
      "reasoning": "Requires contextual understanding of session structure and inheritance of priority, not keyword-based."
    },
    {
      "priority": "Low",
      "rule_text": "Any abstract that mentions the word \u201cprostate\u201d or \u201cmCRPC\u201d or \u201cmCSPC\u201d",
      "approach": "keywords",
      "key_concepts": {
        "keywords": [
          "prostate",
          "mCRPC",
          "mCSPC"
        ],
        "categories": [],
        "contextual_concepts": []
      },
      "exclusions": [
        "ADC",
        "B7H3",
        "HER-2",
        "HER-3",
        "TROP2",
        "Radioligands",
        "RLT",
        "CD28",
        "KLK2",
        "CD3",
        "STEAP1",
        "STEAP2",
        "Novel PARP",
        "PSMA",
        "EZH2",
        "PRC2",
        "AR PROTAC",
        "Ga-68-NGUL",
        "Lu-177-DGUL",
        "FPI-2265",
        "CONV01-\u03b1",
        "225Ac-J591",
        "[255Ac]Ac-PSMA-R2",
        "225Ac-PSMA-617",
        "[225Ac]Ac-FL-020",
        "Ludotadipep (177Lu-FC705)",
        "BAY2315497",
        "225Ac-pelgifatamab (BAY3546828)",
        "225Ac-PSMA-Trillium (BAY3563254)",
        "177Lu-rhPSMA-10.1",
        "64Cu-SAR-BBN",
        "67CU SAR-BBN",
        "177Lu-TLX591",
        "225Ac-TLX592",
        "Pluvicto (Lu-PSMA-617)",
        "[225Ac]-AZD2284",
        "64Cu-SAR-bisPSMA",
        "67Cu-SAR-bisPSMA",
        "177Lu-PSMA-I&T",
        "68Ga-OncoACP3",
        "JANX007",
        "Xaluritamig (AMG509)",
        "REGN5678",
        "REGN4336",
        "REGN7075",
        "ONC-392",
        "Vudalimab",
        "SX-682",
        "Lorigerlimab",
        "BMS-986460",
        "AZD0754",
        "SV-102",
        "CAN-2409",
        "VIR-5500",
        "INKmune",
        "GSK5458514",
        "PT-112",
        "FOR46",
        "BNT324/DB-1311",
        "ABBV-969",
        "infinatamab deruxtecan (I-Dxd)",
        "vobramitamab duocarmizine",
        "ADRX-0405",
        "Xtandi (enzalutamide)",
        "Nubeqa (darolutamide)",
        "saruparib (AZD-5305)",
        "Talzenna (talazoparib)",
        "Rubraca (rucaparib)",
        "cabozantinib",
        "mevrometostat",
        "BMS-986365",
        "opevesostat",
        "ORIC-944",
        "(R)-9bMS",
        "ART-101",
        "ACE-232",
        "ARC-706",
        "ASP5541",
        "GDC-2992 / RO7656594",
        "ENZARAD",
        "PrTK03",
        "DASL-HiCaP",
        "EMBARK",
        "ARASTEP",
        "PSMA-DC",
        "ARANOTE",
        "Capitello-281",
        "TALAPRO-3",
        "PSMAddition",
        "EvoPAR-PRO1",
        "PROpel",
        "TALAPRO-2",
        "TRITON-3",
        "CONTACT-02",
        "PSMAfore",
        "ECLIPSE",
        "SPLASH",
        "CAPitello-280",
        "ProstACT",
        "MEVPRO-1",
        "MEVPRO-2",
        "MEVPRO-3",
        "ALPHABREAK",
        "ARASEC",
        "AcTFirst",
        "PSMAcTION",
        "PSMAndARPI",
        "CONVERGE-01",
        "SatisfACtion",
        "Ideate-Prostate01",
        "rechArge",
        "OMAHA1",
        "OMAHA2",
        "XALute",
        "ARPI (androgen receptor pathway inhibitors)",
        "androgen deprivation therapy",
        "androgen receptor degraders",
        "PARP",
        "PARP inhibitor"
      ],
      "reasoning": "Simple keyword matching for low priority, but must exclude all high priority keywords to ensure mutual exclusivity."
    }
  ]
}